Laboratory of Molecular Immunoregulation, Cancer and Inflammation Program, Center for Cancer Research, National Cancer Institute at Frederick, Frederick, MD 21702, USA.
Exp Cell Res. 2011 Mar 10;317(5):674-84. doi: 10.1016/j.yexcr.2010.10.023. Epub 2010 Nov 4.
Chemokine-like receptor 1 (CMKLR1), also known as ChemR23, and chemokine (C-C motif) receptor-like 2 (CCRL2) are 7-transmembrane receptors that were cloned in the late 1990s based on their homology to known G-protein-coupled receptors. They were previously orphan receptors without any known biological roles; however, recent studies identified ligands for these receptors and their functions have begun to be unveiled. The plasma protein-derived chemoattractant chemerin is a ligand for CMKLR1 and activation of CMKLR1 with chemerin induces the migration of macrophages and dendritic cells (DCs) in vitro, suggesting a proinflammatory role. However, in vivo studies using CMKLR-deficient mice suggest an anti-inflammatory role for this receptor, possibly due to the recruitment of tolerogenic plasmacytoid DCs. Chemerin/CMKLR1 interaction also promotes adipogenesis and angiogenesis. The anti-inflammatory lipid mediator, resolving E1, is another CMKLR1 ligand and it inhibits leukocyte infiltration and proinflammatory gene expression. These divergent results suggest that CMKLR1 is a multifunctional receptor. The chemokine CCL5 and CCL19 are reported to bind to CCRL2. Like Duffy antigen for chemokine receptor (DARC), D6 and CCX-CKR, CCRL2 does not signal, but it constitutively recycles, potentially reducing local concentration of CCL5 and CCL19 and subsequent immune responses. Surprisingly, chemerin, a ligand for CMKLR1, is a ligand for CCRL2. CCRL2 binds chemerin and increases local chemerin concentration to efficiently present it to CMKLR1 on nearby cells, providing a link between CCRL2 and CMKLR1. Although these findings suggest an anti-inflammatory role, a recent study using CCRL2-deficient mice indicates a proinflammatory role; thus, CCRL2 may also be multifunctional. Further studies using CMKLR1- or CCRL2-deficient mice are needed to further define the role of these receptors in immune responses and other cellular processes.
趋化因子样受体 1(CMKLR1),也称为 ChemR23,和趋化因子(C-C 基序)受体样 2(CCRL2)是 7 次跨膜受体,它们是在 20 世纪 90 年代后期根据与已知 G 蛋白偶联受体的同源性克隆的。它们以前是没有任何已知生物学作用的孤儿受体;然而,最近的研究确定了这些受体的配体,它们的功能开始被揭示。血浆蛋白衍生的趋化因子 chemerin 是 CMKLR1 的配体,用 chemerin 激活 CMKLR1 可诱导体外巨噬细胞和树突状细胞(DC)的迁移,提示其具有促炎作用。然而,使用 CMKLR1 缺陷小鼠的体内研究表明该受体具有抗炎作用,这可能是由于招募了耐受原性浆细胞样 DC。chemerin/CMKLR1 相互作用还促进脂肪生成和血管生成。抗炎脂质介质,解析 E1,是另一种 CMKLR1 配体,它抑制白细胞浸润和促炎基因表达。这些相互矛盾的结果表明 CMKLR1 是一种多功能受体。趋化因子 CCL5 和 CCL19 据报道与 CCRL2 结合。像趋化因子受体(DARC)的 Duffy 抗原、D6 和 CCX-CKR 一样,CCRL2 不发出信号,但它持续循环,可能降低 CCL5 和 CCL19 的局部浓度和随后的免疫反应。令人惊讶的是,CMKLR1 的配体 chemerin 也是 CCRL2 的配体。CCRL2 结合 chemerin 并增加局部 chemerin 浓度,以便有效地将其呈递给附近细胞上的 CMKLR1,为 CCRL2 和 CMKLR1 之间提供了联系。尽管这些发现提示其具有抗炎作用,但最近一项使用 CCRL2 缺陷小鼠的研究表明其具有促炎作用;因此,CCRL2 也可能具有多功能性。需要使用 CMKLR1 或 CCRL2 缺陷小鼠进一步研究,以进一步确定这些受体在免疫反应和其他细胞过程中的作用。